Last reviewed · How we verify
Kytril inj.+Kytril tab.
Kytril inj.+Kytril tab. is a 5-HT3 receptor antagonist Small molecule drug developed by LG Life Sciences. It is currently FDA-approved for Chemotherapy-induced nausea and vomiting (CINV), Postoperative nausea and vomiting (PONV), Radiation-induced nausea and vomiting.
Granisetron blocks serotonin 5-HT3 receptors on chemoreceptor trigger zone and vagal afferent nerves to prevent nausea and vomiting.
Granisetron blocks serotonin 5-HT3 receptors on chemoreceptor trigger zone and vagal afferent nerves to prevent nausea and vomiting. Used for Chemotherapy-induced nausea and vomiting (CINV), Postoperative nausea and vomiting (PONV), Radiation-induced nausea and vomiting.
At a glance
| Generic name | Kytril inj.+Kytril tab. |
|---|---|
| Sponsor | LG Life Sciences |
| Drug class | 5-HT3 receptor antagonist |
| Target | 5-HT3 receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology, Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Granisetron is a selective antagonist of serotonin 5-HT3 receptors, which are located on chemoreceptor trigger zone neurons and on the vagal afferent nerves of the gastrointestinal tract. By blocking these receptors, it prevents the transmission of emetic signals to the vomiting center in the brain, effectively suppressing both chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV).
Approved indications
- Chemotherapy-induced nausea and vomiting (CINV)
- Postoperative nausea and vomiting (PONV)
- Radiation-induced nausea and vomiting
Common side effects
- Headache
- Constipation
- Asthenia/fatigue
- Diarrhea
- Abdominal pain
- Fever
Key clinical trials
- Phase 4 Trial to Evaluate the Efficacy and Safety of Sancuso Patch in Chemotherapy-induced Nausea and Vomiting Associated With the Administration of Highly Emetogenic Chemotherapy (HEC) (PHASE4)
- Phase 4 Trial to Evaluate the Efficacy and Safety of Sancuso Patch in CINV (Chemotherapy-induced Nausea and Vomiting) Associated With the Administration of MEC (Moderately Emetogenic Chemotherapy) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Kytril inj.+Kytril tab. CI brief — competitive landscape report
- Kytril inj.+Kytril tab. updates RSS · CI watch RSS
- LG Life Sciences portfolio CI
Frequently asked questions about Kytril inj.+Kytril tab.
What is Kytril inj.+Kytril tab.?
How does Kytril inj.+Kytril tab. work?
What is Kytril inj.+Kytril tab. used for?
Who makes Kytril inj.+Kytril tab.?
What drug class is Kytril inj.+Kytril tab. in?
What development phase is Kytril inj.+Kytril tab. in?
What are the side effects of Kytril inj.+Kytril tab.?
What does Kytril inj.+Kytril tab. target?
Related
- Drug class: All 5-HT3 receptor antagonist drugs
- Target: All drugs targeting 5-HT3 receptor
- Manufacturer: LG Life Sciences — full pipeline
- Therapeutic area: All drugs in Oncology, Anesthesia
- Indication: Drugs for Chemotherapy-induced nausea and vomiting (CINV)
- Indication: Drugs for Postoperative nausea and vomiting (PONV)
- Indication: Drugs for Radiation-induced nausea and vomiting
- Compare: Kytril inj.+Kytril tab. vs similar drugs
- Pricing: Kytril inj.+Kytril tab. cost, discount & access